DESCRIPTION
A 59-year-old asymptomatic woman presented for follow-up CT thorax, abdomen and pelvis (CT-TAP). Fifteen months previously she underwent a left radical nephrectomy for a T1bN0MO, 5.5 cm Fuhrman grade 4 clear cell renal cell carcinoma (CCRCC) (figure 1).
The CT-TAP revealed a new 3.6 cm peripherally enhancing, centrally necrotic, intramural lesion in the fundus of the stomach (figure 2). It was decided to biopsy the lesion via oesophago-gastro duodenoscopy (OGD). It was not apparent on direct visualisation of the stomach mucosa, thus confirming its submucosal location. In light of its location, as well as the onset of upper gastrointestinal symptoms, lack of histological diagnosis or evidence of metastatic disease, a laparoscopic sleeve gastrectomy was performed. A tan intramural mass in the fundus of the stomach was 
Figure 3
This is a comparison between the resected primary left kidney (left) and the intramural metachronous stomach lesion (right). The kidney has been bivalved to reveal a large, well-circumscribed tumour with a variegated tan/yellow cut surface (red arrow) and a prominent cystic area, responsible for the heterogenous appearance at CT (green arrow). Note the overall similar gross appearance to the sleeve gastrectomy specimen. Normal stomach mucosa is adjacent to the ruler.
Images in…
The annual incidence of RCC has risen in the USA and Europe by 3% per year during the last several decades. Approximately 20% of patients will have metastatic disease at the time of diagnosis with 50% developing metachronous metastasis post nephrectomy. 1 CCRCC is known for unusual sites of metastatic spread and can typically involve the lung, bones, liver, lymph nodes or adrenal glands. A metastasis from any cause to the stomach is exceedingly rare and can account for between 0.3% and 0.8% of all gastric neoplasia. 2 Such is the rarity of gastric metastasis from all histological subtypes of renal cell carcinoma, there are only approximately 25-30 cases described in the literature. The largest case series is of five patients over a 21-year time period in 2082 patients.
3 This is the best current level of prognostic evidence for gastric RCC metastases, which usually presents late in the disease process. The majority of patients show concomitant tumour spread to other organs with poor outcome. Our patient has subsequently developed peritoneal metastases and is being treated with sunitinib, an inhibitor of receptor tyrosine kinase. 
